Seattle biotech firm scores $85 million for work on Alzheimer’s drug, despite hurdles of coronavirus pandemic

Athira Pharma, a Seattle-based biotechnology company, secured $85 million in a Series B round. The additional financing will support Athira Pharma’s Phase 2/3 Alzheimer’s clinical trial of NDX-1017, a drug that aims to enhance and restore brain function.

READ THE STORY at The Seattle Times »